Clinical Cancer Research Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hose, C.
Right arrow Articles by Monks, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hose, C.
Right arrow Articles by Monks, A.
Clinical Cancer Research Vol. 11, 6370-6381, September 1, 2005
© 2005 American Association for Cancer Research


Cancer Therapy: Preclinical

Transcriptional Profiling Identifies Altered Intracellular Labile Iron Homeostasis as a Contributing Factor to the Toxicity of Adaphostin: Decreased Vascular Endothelial Growth Factor Secretion Is Independent of Hypoxia-Inducible Factor-1 Regulation

Curtis Hose1, Gurmeet Kaur2, Edward A. Sausville2 and Anne Monks1

Authors' Affiliations: 1 SAIC Frederick, Inc., Screening Technologies Branch, Laboratory of Functional Genomics, National Cancer Institute Frederick, Frederick, Maryland and 2 Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland

Requests for reprints: Anne Monks, SAIC Frederick, Inc., National Cancer Institute Frederick, P.O. Box B, Frederick MD, 21702. Phone: 301-846-5528; Fax: 301-846-6081; E-mail: monks{at}dtpax2.ncifcrf.gov.

Purpose: Adaphostin was developed as an inhibitor of the p210bcr-abl tyrosine kinase, but as its activity is not limited to tumor cell lines containing this translocation, transcriptional profiling was used as a tool to elucidate additional mechanisms responsible for adaphostin cytotoxicity.

Experimental design: Profiles of drug-induced transcriptional changes were measured in three hematopoietic cell lines following 1 and 10 µmol/L adaphostin for 2 to 6 hours and then confirmed with real-time reverse transcription-PCR (2-24 hours). These data indicated altered iron homeostasis, and this was confirmed experimentally. Alteration of vascular endothelial growth factor (VEGF) secretion through hypoxia-inducible factor-1 (HIF-1) regulation was also investigated.

Results: Drug-induced genes included heat shock proteins and ubiquitins, but an intriguing response was the induction of ferritins. Measurement of the labile iron pool showed release of chelatable iron immediately after treatment with adaphostin and was quenched with the addition of an iron chelator. Pretreatment of cells with desferrioxamine and N-acetyl-cysteine reduced but did not ablate the sensitivity of the cells to adaphostin, and desferrioxamine was able to modulate adaphostin-induced activation of p38 and inactivation of AKT. VEGF secretion was shown to be reduced in cell lines after the addition of adaphostin but was not dependent on HIF-1.

Conclusions: Adaphostin-induced cytotoxicity is caused in part by a rapid release of free iron, leading to redox perturbations and cell death. Despite this, reduced VEGF secretion was found to be independent of regulation by the redox responsive transcription factor HIF-1. Thus, adaphostin remains an interesting agent with the ability to kill tumor cells directly and modulate angiogenesis.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
L. H. Stockwin, M. A. Bumke, S. X. Yu, S. P. Webb, J. R. Collins, M. G. Hollingshead, and D. L. Newton
Proteomic Analysis Identifies Oxidative Stress Induction by Adaphostin
Clin. Cancer Res., June 15, 2007; 13(12): 3667 - 3681.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. B. Le, M. K. Hailer, S. Buhrow, Q. Wang, K. Flatten, P. Pediaditakis, K. C. Bible, L. D. Lewis, E. A. Sausville, Y.-P. Pang, et al.
Inhibition of Mitochondrial Respiration as a Source of Adaphostin-induced Reactive Oxygen Species and Cytotoxicity
J. Biol. Chem., March 23, 2007; 282(12): 8860 - 8872.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
I. Mukhopadhyay, E. A. Sausville, J. H. Doroshow, and K. K. Roy
Molecular Mechanism of Adaphostin-mediated G1 Arrest in Prostate Cancer (PC-3) Cells: SIGNALING EVENTS MEDIATED BY HEPATOCYTE GROWTH FACTOR RECEPTOR, c-Met, AND p38 MAPK PATHWAYS
J. Biol. Chem., December 8, 2006; 281(49): 37330 - 37344.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.